Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heregulin
100%
Drug Resistance
100%
ERBB2
100%
ErbB4
40%
Breast Cancer
30%
Doxorubicin
20%
Immunohistochemistry
20%
Overexpression
20%
One-group
10%
Co-expression
10%
Clinical Trials
10%
Resistance Sensitivity
10%
Tumor Progression
10%
Growth Factors
10%
Node-negative Breast Cancer
10%
Constitutive Production
10%
Paraffin-embedded Specimens
10%
Therapeutic Endpoints
10%
Oncogene Products
10%
Invasive Potential
10%
Cytotoxic Therapy
10%
ErbB-2 Receptor
10%
In Situ Hybridization
10%
Quantitative PCR
10%
MCF-7 Cells
10%
Poor Prognosis
10%
Therapeutic Decision-making
10%
Invasive Breast Cancer
10%
ErbB
10%
Biological Agents
10%
Metastatic Breast Cancer
10%
Breast Cancer Progression
10%
Breast Cancer Patients
10%
In Situ
10%
Mechanistic Aspects
10%
Chemotherapy
10%
Estrogen
10%
Small Proteins
10%
ER-positive
10%
VP16
10%
Cancer Cells
10%
Topoisomerase II
10%
Receptor Expression
10%
Antiestrogen
10%
Doxorubicin Resistance
10%
Primary Breast Cancer
10%
Tumor Specimens
10%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
Doxorubicin
66%
Neu Differentiation Factor
50%
Oncogene
22%
In Situ Hybridization
22%
Cancer Cell
22%
Tumor Progression
22%
Growth Factor
22%
DNA Gyrase
22%
Reverse Transcription Polymerase Chain Reaction
22%
Clinical Trial
22%